Treatment of Somatization Disorder With Nefazodone: A Prospective, Open-Label Study

References

• Escobar JI, Burnam MA, Kano M, Karno M, Forsythe A, Golding JM: Somatization in the community. Arch Gen Psych 1987; 44:713–718
   PubMed Web of Science ®Google Scholar
• Swartz M, Blazer D, George L, Landerman R: Somatization disorder in a community population. Am J Psychiatry 1986; 11:1403–1408
   Google Scholar
• Fink P, Sorensen L, Engberg M, Holm M, Munk-Jorgensen P: Somatization in primary care. Prevalence, health care uti-lization, and general practitioner recognition. Psychosomatics 1999; 40(4):330–338
   Google Scholar
• Smith GR: Somatization Disorder in the Medical Setting. DHHS Pub. No. (ADM)90-1631. Washington, DC: US Gov-ernment Printing Office; 1990
   Google Scholar
• Smith GR: The course of somatization and its effects on uti-lization of health care resources. Psychosomatics, 1994; 35:263–267
   PubMed Web of Science ®Google Scholar
• Escobar JI, Canino G: Unexplained physical complaints: Psy-chopathology and epidemiological correlates. Brit J Psychiatry 1989; 14:24–27
   Google Scholar
• Escobar JI, Golding JM, Hough RL, Karno M, Burman MA, Wells KB: Somatization in the community: Relationship to disability and use of services. Am J Public Health 1987; 77:837–840
   PubMed Web of Science ®Google Scholar
• Escobar JI, Waitzkin H, Gara MA, Silver RC, Holman A: Abridged Somatization A study in primary care. Psychosom Med 1998; 60:466–472
   PubMed Web of Science ®Google Scholar
• O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K: Antidepressant therapy for unexplained symptoms and symptom syndromes. J Family Practice 1999; 48(12):980–990
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB: Physical symptoms in primary care: Predictors of psychiatric disorder and functional impairment. Arch Fam Med 1994; 3:774–779
   PubMedGoogle Scholar
• Smith GR: The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, of pain. Gen Hosp Psychiatry 1992; 14:265–272
   PubMedGoogle Scholar
• Noyes R, Happel RL, Muller BA, Holt CS, Kathol RG, Sieren LR, Amos JJ: Fluvoxamine for somatoform disorders: An open trial. Gen Hosp Psychiatry 1998; 20:339–344
   PubMedGoogle Scholar
• Escobar JI: Pharmacologic treatment of somatization/ hypochondriasis. Overview of somatization; diagnosis, epi-demiology, and management. Psychopharmacology Bull 1996; 32:589–596
   Google Scholar
• Allen LA, Gara MA, Escobar JI, Waitzkin H, Silver RC: Som-atization. A debilitating syndrome in primary care. Psychoso-matics 2001; 42:63–67
   Google Scholar
• Rickels K, Robinson DS, Schweizer E, Marcus RN, Roberts DL: Nefazodone: Aspects of efficacy. J Clin Psychiatry 1995; 56(Suppl 6):43–46
   PubMedGoogle Scholar
• Hedges DW, Reimherr FVV, Strong RE, Halls CH, Rust C: An open trial of nefazodone in adult patients with general-ized anxiety disorder. Psychopharmacol Bull 1996; 32(4):671–676
   PubMedGoogle Scholar
• Van Ameringen M, Mancini C, Oakman JM: Nefazodone in social phobia. I Clin Psychiatry 1999 Feb; 60(2):96–100
   PubMed Web of Science ®Google Scholar
• Zisook S, Chentsova-Dutton YE, Smith-Vaniz A, Kline NA, Ellenor GL, Kodsi AB, Gillin IC: Nefazodone in patients with treatment-refractory posttraumatic stress disorder. J Clin Psy-chiatry 2000 Mar; 61(3):203–208
   Google Scholar
• Zajecka JM: The effect of nefazodone on comorbid anxiety symptoms associated with depression: Experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996; 57(Suppl 2):10–14
   PubMedGoogle Scholar
• Hickie I: Nefazodone for patients with chronic fatigue syn-drome. Aust N Z J Psychiatry 1999 Apr; 33(2):278–280
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994
   Google Scholar
• Escobar JI, Manu P, Matthews D, Lane T, Swartz M, Carino G: Medically unexplained physical symptoms, somatization dis-order and abridged somatization Studies with the Diagnostic Interview Schedule. Psychiatr Dev 1989; 3:235–245
   Google Scholar
• First MB, Spritzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edi-tion, Biometrics Research Department, New York State Psy-chiatric Institute, New York, NY, 1995
   Google Scholar
• Robins LN, Wing J, Wittchen H, Helzer JE, Babor TF, et al.: The Composite International Diagnostic Interview. Arch Gen Psychiatry 1988; 45:1069–1077
   PubMed Web of Science ®Google Scholar
• Guy W: ECDEU Assessment Manual for Psychopharmacol-ogy, Revised Edition. Department of Health, Education, and Welfare, National Institute of Mental Health, Publication No. ADM76-338, Rockville, MD, 1976
   Google Scholar
• Hays RD, Sherbourne CD, Mazel RM: The RAND 36-item Health Survey 1.0. Health Economics 1993; 2:217–227
   PubMedGoogle Scholar
• Hamilton M: Hamilton Depression Scale. In, ECDEU Assess-ment Manual for Psychopharmacology, Revised Edition (ed. W Guy), pp. 179–192,1976. Rockville, Maryland: National In-stitute of Mental Health
   Google Scholar
• Hamilton M: The assessment of anxiety status by rating. Br J Med Psychol 1959; 32:50–55
   PubMed Web of Science ®Google Scholar
• Speckens AE, van Hemert AM, Bolk JH, etal.: The acceptabil-ity of psychological treatment in patients with medically unex-plained physical symptoms. J Psychosom Res 1995; 39:855–863
   Google Scholar
• Barsky AJ, Borus JR: Functional somatic syndromes. Ann In-tern Med. 1999; 130:910–921
   PubMed Web of Science ®Google Scholar
• Morrison .1, Herbstein J: Secondary affective disorder in women with somatization. Comp Psychiatry 1988; 29:433–440
   PubMed Web of Science ®Google Scholar